A new generation
of RNA therapeutics
RNA therapeutics have come of age, with an expanding landscape of pre-clinical, clinical and commercial validation across many modalities. However, efficient and safe delivery of the therapeutic cargo into target cells remains a barrier to RNA therapeutics reaching their full potential.
PYC Therapeutics combines world-leading RNA therapeutics design with a revolutionary delivery technology based on a proprietary library of naturally derived Cell Penetrating Peptides (CPPs) to solve this delivery challenge.
OUR SCIENCEChanging the lives
of patients with
inherited diseases
We are building a pipeline of highly precise RNA therapeutics, leveraging the latest generation in Antisense Oligonucleotides called Phosphorodiamidate Morpholino Oligomers (PMOs). These PMOs are delivered safely and effectively to target cells using our proprietary library of naturally derived peptides.
We currently have 3 peptide conjugated PMOs (or PPMOs) in preclinical development, directed toward high unmet need in inherited ocular diseases. We continue to build out our pipeline with a focus on additional ocular therapies and therapies to address important neurodegenerative diseases.
OUR PIPELINE
